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Summary
The costimulatory molecule CTLA-4 is a potent
downregulator of T cell responses. Although localized
mostly in intracellular compartments, little is under-
stood regarding the mechanism that regulates its
transport to the cell surface. In this study, we demon-
strated that the adaptor TRIM (T cell receptor-interact-
ing molecule) bound to CTLA-4 in the trans Golgi
network (TGN) and promoted transport of CTLA-4 to
the surface of T cells. Increased TRIM expression aug-
mented surface CTLA-4 expression, and pulse-chase
analysis showed a more rapid transport of CTLA-4 to
the cell surface. A reduction of TRIM expression by
small hairpin RNAs reduced the expression of surface
CTLA-4. This resulted in a more localized pattern of
CTLA-4 in the TGN. Altered CTLA-4 expression by
TRIM was accompanied by corresponding changes in
coreceptor-mediated effects on cytokine production
and proliferation. Our findings identify a role for TRIM
as a chaperone in regulating CTLA-4 expression and
function by enhancing CTLA-4 transport to the surface
of T cells.
Introduction
The costimulatory molecules CD28 and CTLA-4 deter-
mine the ultimate outcome of the immune response after
ligation of the T cell receptor (TCR)–CD3 complex. Both
bind to CD80 and CD86 and are required for optimal
T cell activation (Bluestone, 1995; Linsley, 1995; Thomp-
son, 1995). In contrast to CD28, which enhances and
sustains T cell responses, CTLA-4 potently inhibits T cell
activation (Krummel and Allison, 1995; Linsley, 1995;
Walunas et al., 1994). CTLA-4-deficient (Ctla-42/2) mice
*Correspondence: hs383@cam.ac.ukshow an autoimmune phenotype with organ destruction
(Tivol et al., 1995; Waterhouse et al., 1995). Various
mechanisms have been proposed to account for the
molecular mechanism by which CTLA-4 generates inhib-
itory signals. Reported mechanisms include ectodomain
competition for CD28 binding to CD80 and CD86
(Masteller et al., 2000), disruption of CD28 localization
at the immunological synapse (Pentcheva-Hoang et al.,
2004), modulation of phosphatases PP2A and SHP-2
(Chuang et al., 2000; Lee et al., 1998; Marengere et al.,
1996), and interference with lipid raft expression (Chi-
kuma et al., 2003; Darlington et al., 2002; Martin et al.,
2001; Rudd et al., 2002). CTLA-4 engagement of CD80
and CD86 on dendritic cells can also induce the release
of indoleamine 2,3-dioxygenase (IDO) (Boasso et al.,
2004; Fallarino et al., 2003). In addition, we have demon-
strated that CTLA-4 is a potent inducer of integrin adhe-
sion, and can reverse the stop signal needed for stable
T cell–APC conjugation (Schneider et al., 2005, 2006).
One of the unusual characteristics of CTLA-4 is that it
is primarily located in intracellular compartments (Alegre
et al., 1996; Leung et al., 1995). Little of the coreceptor
can be detected on the surface of cells, even during its
optimal expression after T cell activation. This tight reg-
ulation is presumably due to the need to control surface
expression of this potent coreceptor. Two pools of
intracellular CTLA-4 have been described, in the trans
Golgi apparatus (TGN) and in endo- and lysosomal com-
partments (Alegre et al., 1996; Iida et al., 2000; Leung
et al., 1995; Linsley et al., 1996). TCR ligation and cal-
cium ionophores can induce CTLA-4 release to the cell
surface; however, the mechanism is unknown (Linsley
et al., 1996). The other event known to affect CTLA-4
expression involves the mutation of the YVKM motif in
CTLA-4, which can increase expression mediated by
impaired internalization via the clathrin adaptor complex
AP-2 (Yi et al., 2004). Nonphosphorylated CTLA-4 can
bind to AP-1 and AP-2 tetramers that regulate trafficking
and endocytosis of CTLA-4, respectively (Bradshaw
et al., 1997; Chuang et al., 1997; Schneider et al., 1999;
Shiratori et al., 1997; Zhang and Allison, 1997). AP-1
binding to CTLA-4 mediates its transport from the Golgi
apparatus to the lysosomal compartment for degrada-
tion (Schneider et al., 1999). Once on the cell surface,
other mechanisms (i.e., binding to AP-2) regulate its
endocytosis (Shiratori et al., 1997; Zhang and Allison,
1997). Phosphorylation of CTLA-4 by the kinases
p56lck, p59fyn, and Rlk can inhibit these events (Brad-
shaw et al., 1997; Chuang et al., 1997; Miyatake et al.,
1998; Schneider et al., 1998).
Adaptor proteins are essential for precise signal trans-
duction by allowing the formation of signaling scaffolds
(Rudd, 1999; Samelson 2002). Two main groups of
adaptor proteins can be distinguished: cytosolic and
transmembrane adaptor proteins. An array of trans-
membrane adaptor proteins (TRAPs) has been identified
including LAT (linker for activation of T cells), LIME (lck
interacting membrane protein), TRIM (T cell receptor-
interacting molecule), SIT (SHP2 interacting transmem-
brane adaptor protein), PAG/Cbp (protein associated
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809with GEMs/Csk binding protein), and LAX (linker for
activation of X) (Kliche et al., 2004).
Of these, TRIM (official gene name trat1) is a 30 Kd type
III transmembrane protein, which is expressed in human
T lymphocytes and NK cells (Bruyns et al., 1998; Kirch-
gessner et al., 2001). It comprises a short 8 amino acid
extracellular domain, a 19 amino acid transmembrane
region, and a 159 amino acid cytosolic tail. Its cytoplas-
mic tail contains several tyrosine motifs with the poten-
tial to bind to Src-homology 2 (SH2) domains of signaling
proteins. Upon TCR stimulation, TRIM becomes rapidly
tyrosine phosphorylated and associates with the p85
subunit of the lipid kinase PI3-kinase (Bruyns et al.,
1998). Association of TRIM with the TCRz-CD3 complex
has been shown in Jurkat T cells and human peripheral
blood lymphocytes (PBLs) (Bruyns et al., 1998). Overex-
pression of TRIM in Jurkat T cells has been reported to
induce an increase in TCR surface expression, although
this does not occur in primary T cells (Kirchgessner et al.,
2001; Ko¨lsch et al., 2006).
Given the importance of CTLA-4 to T cell immunity,
a major outstanding question concerns the mechanism
by which the coreceptor is shuttled to the cell surface
to downregulate the immune response. In this study,
we demonstrate that TRIM facilitates shuttling of
CTLA-4 from the TGN to the surface of T cells. The adap-
tor was found to bind and colocalize with CTLA-4 in the
TGN. TRIM overexpression increased CTLA-4 expres-
sion and its ability to inhibit T cell proliferation and inter-
leukin-2 (IL-2) production. Moreover, the reduction of
TRIM expression by shRNA reduced CTLA-4 cell-
surface expression and CTLA-4-mediated inhibition of
cytokine release. Further, subcellular distribution of
CTLA-4 was altered in TRIM knockdown cells. Together,
our findings identified a role for TRIM as a chaperone
in modulating CTLA-4 surface expression and thus regu-
lating T cell function.
Results
TRIM Binds to CTLA-4 and CD3, but Not to CD28
The transmembrane adaptor protein was initially identi-
fied as a protein that coprecipitates and comodulates
the TCR–CD3 complex (Bruyns et al., 1998; Kirchgessner
et al., 2001). TRIM was reported to specifically associate
with the TCRz chain, but not with coreceptors such as
CD28, CD2, CD4, and CD8 (Bruyns et al., 1998). However,it was not known whether TRIM binds to other receptors.
In order to assess whether TRIM associates with CTLA-
4, DC27.10 hybridoma T cells expressing CTLA-4
(DC27.10-CTLA-4) were initially transfected with HA-
tagged TRIM and subjected to immunoprecipitation
with anti-CD3 or anti-CTLA-4. Anti-CTLA-4 readily
coprecipitated TRIM when compared to mock trans-
fected cells (Figure 1A). This binding was considerably
higher than seen with CD3. Further, TRIM bound selec-
tively to CTLA-4 but not to CD28 (Figure 1A; Bruyns
et al., 1998) as shown by DC27.10 hybridoma T cells
expressing CD28 (DC27.10-CD28) transfected with HA-
tagged TRIM or mock and immunoprecipitated with
anti-CD28.
To assess the binding of endogenous TRIM to CTLA-
4, DC27.10-CTLA-4 cells and human PBLs were lysed
and subjected to precipitation (Figure 1B). Anti-CD8,
anti-CD4, anti-CD28, and anti-CTLA-4 immunoprecipi-
tates were subjected to blotting for endogenous TRIM
with anti-TRIM under nonreducing condition. Although
no binding of endogenous TRIM to CD4, CD8, and
CD28 was observed, endogenous TRIM was readily
coprecipitated with CTLA-4 in DC27.10-CTLA-4 cells
and human PBLs. These observations confirm that
endogenous TRIM and CTLA-4 interact in primary
T cells.
CTLA-4 interacts with the lipid kinase phosphatidyli-
nositol 3-kinase (PI3-K) via SH2 domain binding to the
YVKM motif (Schneider et al., 1995). Mutation of the
Y-201 residue disrupts PI3-K binding (Schneider et al.,
1999). Similarly, AP-1 and AP-2 binding was abrogated
in the CTLA-4-Y201F mutant (Schneider et al., 1999).
To assess whether TRIM binding to CTLA-4 could occur
independently of the binding of PI3-K and the AP-1 and
AP-2 complexes, anti-CTLA-4 was used to precipitate
TRIM from cells expressing wild-type and the CTLA-4
Y201F mutant (Figure 1C). Under these conditions,
TRIM was coprecipitated at equal amounts from wild-
type and Y201F mutant cells. In addition, mutation of
the two tyrosines Y201 and Y218 in CTLA-4 cytoplasmic
tail had no effect on the binding of TRIM to CTLA-4.
These observations demonstrated that TRIM binds to
CTLA-4 independently of PI3-K and AP-1 and AP-2
complex binding.
As a further control, it was also important to assess
whether other lymphoid components such as the
TCRz-CD3 complex were involved in the CTLA-4–TRIMFigure 1. TRIM Binds to CD3 and CTLA-4, but Not CD28
(A) DC27.10-CTLA-4 (lanes 1–4) and DC27.10-CD28 cells (lanes 5, 6) transfected with mock (lanes 1, 2, 5) or HA-TRIM (lanes 3, 4, 6) were immu-
noprecipitated with anti-CTLA-4 (lanes 2, 4), anti-CD3 (lanes 1, 3), and anti-CD28 (lanes 5, 6; nonreducing condition) and immunoblotted with
anti-HA (lanes 1–6). Expression of HA-TRIM is shown in cell lysates immunoblotted with anti-HA (bottom). The results are representative of three
independent experiments.
(B) DC27.10-CTLA-4 cells (left) and PBLs (right) were precipitated with anti-CD8 (lanes 1, 3), anti-CD4 (lane 4), anti-CD28 (lane 5), or anti-CTLA-4
(lanes 2, 6) and blotted for endogenous TRIM (lanes 1–6, nonreducing condition). The lower panel shows the expression of endogenous TRIM in
cell lysate. Similar results were obtained from another independent experiment.
(C) COS cells cotransfected with HA-TRIM and either mock (lane 1), CTLA-4 WT (lane 2), CTLA-4 Y201F mutant (lane 3), CTLA-4 Y218F mutant
(lane 4), and CTLA-4Y201F-Y218F mutant (lane 5) were precipitated with anti-CTLA-4 and blotted with anti-HA. Expression level of HA-TRIM in
cell lysates is shown in the lower panel.
(D) COS cells cotransfected with mock and CTLA-4 (lane 1) or HA-TRIM and CTLA-4 (lane 2) were precipitated with anti-CTLA-4 and blotted with
anti-HA (lanes 1, 2). Expression of HA-TRIM is shown in cell lysates immunoblotted with anti-HA (bottom).
(E) HA-TRIM-transfected DC27.10-CTLA-4 cells were either first precipitated with anti-CD3 (lane 1) and, after preclearing, subjected to anti-
CTLA-4 precipitation (lane 2), or first precipitated with anti-CTLA-4 (lane 3), followed by two anti-CD3 precipitations (lanes 4, 5) and blotted
for HA-TRIM. Lanes 6 and 7 show CD3 depletion by one anti-CD3 precipitation from TRIM-transfected cells. Densitometric analysis of CTLA-
4 and CD3-precipitated amounts of TRIM is shown in the middle panel. Right: DC27.10-CTLA-4 cells were stained for CD3 or CTLA-4 and an-
alyzed by flow cytometry. Results in (C)–(E) are representative of three independent experiments.
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(A) DC27.10-CTLA-4 and DC27.10-CD28 cells were transfected with TRIM or mock, respectively. After 24 hr, cells were stained with anti-CTLA-4.
Subsequently, cells were fixed with 4% PFA, permeabilized with saponin, and stained for HA-TRIM with anti-HA. HA-negative and HA-positive
cells were gated for analysis. Additionally, cells were stained for CD3 and CD28 expression, with CD3 FITC or CD28 PE-labeled mAbs, respec-
tively (bottom). Results are representative of at least five experiments.
(B) To monitor CTLA-4 surface expression of newly synthesized CTLA-4 in mock (lanes 1–3) or TRIM (lanes 4–6)-transfected DC27.10-CTLA-4
cells, cells were pulsed with [35S]methionine for 20 min and chased with nonradioactive methionine for the indicated periods of time in the pres-
ence of ionomycin (1 mM). Surface CTLA-4 (sCTLA-4) from both transfectants was precipitated by preincubating labeled cells with anti-CTLA-4 at
4C, followed by washing and immunoprecipitation. Lysates were subjected to a round of preclearing with Protein A-Sepharose, followed by
a second precipitation to purify intracellular CTLA-4 (iCTLA-4). The precipitates were analyzed by 10% SDS-PAGE (left); densitometric measure-
ment of intracellular (bottom) and surface (top) CTLA-4, relative to maximum signal, is shown in the right panel. Similar results were obtained from
two other independent experiments.binding. As mentioned, TRIM has previously been re-
ported to associate with the TCRz-CD3 complex on
T cells (Bruyns et al., 1998; Kirchgessner et al., 2001).
For this, CTLA-4 and HA-TRIM were coexpressed in
COS cells, which are nonlymphoid cells, and assessed
for binding (Figure 1D). Anti-CTLA-4 coprecipitated
TRIM from TRIM-transfected, but not from mock trans-
fected, cells. This indicated that TRIM could bind to
CTLA-4 independently of the TCRz-CD3 complex and
other lymphoid components. To compare the amount
of TRIM binding to the TcRz-CD3 complex versus
CTLA-4, an initial precipitation was carried out with
anti-CD3 followed, after preclearing, by a second precip-
itation with anti-CTLA-4 from the CD3-depleted lysate.
Given the normal limitations of different antibody affini-
ties, we observed about five times more TRIM associated
with CTLA-4 than with TcRz-CD3 (Figure 1E). This was
also observed when the first precipitation was done
with anti-CTLA-4 and, after preclearing, with anti-CD3.
An additional anti-CD3 precipitation was ineffective as
also shown with sequential anti-CD3 precipitationsonly. This higher amount of binding of CTLA-4 to TRIM
occurred even in the presence of 1% Triton X-100 and oc-
curred under conditions where the expression levels of
TCRz-CD3 and CTLA-4 were comparable (Figure 1E).
Thus, CTLA-4 precipitated TRIM in the absence of
TcRz-CD3, and the amount of CTLA-4-associated
TRIM was higher than observed with CD3–TRIM.
TRIM Upregulates CTLA-4 Surface Expression
The CTLA-4–TRIM interaction and their intracellular
localization suggested that TRIM might regulate the
surface expression of the coreceptor. The mechanism
that regulates CTLA-4 has been a major question in
CTLA-4 biology with implications to the regulation of T
cell function. Previous studies have implicated the
Y201 residue in controlling the expression of surface
CTLA-4 (sCTLA-4) (Yi et al., 2004; Leung et al., 1995).
CTLA-4 expression was assessed on the surface of
DC27.10-CTLA-4 cells that had been transfected with
HA-TRIM (Figure 2A). Expression of HA-TRIM increased
the mean fluorescence intensity of sCTLA-4 expression.
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tion by CTLA-4
(A) Preactivated human peripheral T cells were transfected with TRIM or mock with Amaxa nucleofection. TRIM- or mock transfected PBLs were
stimulated with 1 mM ionomycin for up to 2 hr in the presence of anti-CTLA-4. Cells were fixed, permeabilized, and stained for HA-TRIM. HA-
TRIM-expressing cells were gated, and total cell-associated PE fluorescence representing surface and internalized CTLA-4 was analyzed in
HA-FITC-positive cells compared to the mock transfected sample. To determine internalized CTLA-4, cells were treated with PBS (pH 2) before
HA-TRIM staining. Total and internalized CTLA-4-PE fluorescence is shown.
(B) The difference between total CTLA-4 staining and internalized material representing CTLA-4 surface staining is shown.
(C) TRIM- or mock transfected PBLs were stimulated with ionomycin (1 mM) for up to 3 hr. At the indicated time points, surface CD3 (sCD3)
expression was analyzed with anti-CD3. Results in (A)–(C) are representative of four independent experiments.
(D) TRIM- or mock transfected DC27.10-CTLA-4 cells (left) were stimulated with plate-bound mAbs for 24 hr (anti-CD3, 1 mg/ml; anti-CTLA-4, 10
mg/ml or 20 mg/ml) as indicated. Supernatants were analyzed for IL-2 by ELISA. Percentage of inhibition in anti-CD3- and anti-CTLA-4-treated
cells was calculated in comparison to anti-CD3-stimulated cells. TRIM- or mock transfected PBLs (right) were stimulated with plate-bound
mAbs for 24 hr (anti-CD3 2 mg/ml, anti-CTLA-4 20 mg/ml) and mitomycin C-treated APCs (5:1) as indicated. [3H]thymidine was added after 24
hr and [3H]thymidine incorporation was measured. Percentage of inhibition in anti-CD3- and anti-CTLA-4-treated cells was calculated in
comparison to anti-CD3-stimulated cells. Bar graphs show mean 6 SD. Similar results were obtained from at least two other independent
experiment.In contrast, TCR-CD3 and CD28 expression was not af-
fected. These findings indicate that an increase in TRIM
expression can increase the expression of sCTLA-4.
In another approach, pulse-chase analysis was used
to track CTLA-4 from intracellular compartments to the
cell surface. Mock and TRIM-transfected cells were
pulsed with [35S]methionine for 20 min followed by
a chase with nonradioactive methionine for 30–60 min.
Surface CTLA-4 from both transfectants was then pre-
cipitated by preincubating the labeled cells with anti-
CTLA-4, followed by washing and immunoprecipitation
(Figure 2B). The remaining material was then subjected
to a second precipitation in order to precipitate the re-
maining intracellular CTLA-4 (iCTLA-4). Under these
conditions, it was evident that pulse-labeled CTLA-4 ap-
peared more quickly and at higher amounts on the sur-
face of T cells in TRIM-transfected cells. The difference
in CTLA-4 surface expression between mock and TRIM
transfectants was most prominent after 30 and 60 min
stimulation (in average three times greater than inmock transfectants). Even with TRIM expression, the
amount of sCTLA-4 comprised only a small portion of
total CTLA-4 in cells. Overall, these findings indicate
that the mere expression of TRIM increased the rate
and amount of sCTLA-4 released from intracellular
compartments.
TRIM Leads to Enhanced CTLA-4 Cycling
Having established that TRIM increased the transport of
CTLA-4 to the cell surface, it was also important to de-
termine whether the increase in sCTLA-4 was accompa-
nied by increased receptor internalization. For this,
CTLA-4 was labeled with anti-CTLA-4-PE, continuously
present in the medium, during stimulation by ionomycin
(Figure 3) or anti-CD3 (data not shown) of primary T cells.
Total cell-associated PE-fluorescence representing sur-
face and internalized CTLA-4 was analyzed at different
times. Consistent with the pulse-chase analysis, total
cell-associated PE-fluorescence was higher in HA-
TRIM-transfected cells than in mock transfectants
Immunity
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CTLA-4
(A) D2, D11, and D20 DC27.10-CTLA-4 TRIM KD cells (lanes 2–4, 6–8, 10–12, 14–16, 18–20) were compared with wild-type DC27.10-CTLA-4 cells
(lanes 1, 5, 9, 13, 17) for the expression of TRIM (lanes 1–4), VAV-1 (lanes 5–8), SLP-76 (lanes 9–12), MAPK (lanes 13–16), and actin (lanes 17–20) by
immunoblotting.
(B) DC27.10-CTLA-4 TRIM KD and WT cells were stained for CTLA-4 and CD3 surface expression. FACS profiles and percentage of CTLA-4 and
CD3 surface expression in DC27.10-CTLA-4 TRIM KD cells relative to WT cells are shown.
(C) DC27.10-CTLA-4 TRIM KD and WT cells were stimulated with plate-bound anti-CD3 and anti-CD3 and CTLA-4 for 24 hr (anti-CD3 1 mg/ml,
anti-CTLA-4 10 mg/ml). Supernatants were analyzed for IL-2 by ELISA. Percentage of inhibition in anti-CD3 and anti-CTLA-4-treated cells was
calculated in comparison to anti-CD3-stimulated cells. Bar graphs show mean 6 SD. Similar results were obtained from at least three other
independent experiments.throughout the stimulation period. The increase in
fluorescence intensity was more pronounced when
compared to mock transfected cells (Figure 3A). Total
cell-associated PE fluorescence was then compared
to the amount of internalized PE-labeled CTLA-4. This
was determined by treatment with acidified PBS to re-
move surface-bound antibody, as described previously
(Cefai et al., 1998). Consistent with increased CTLA-4
expression, TRIM-transfected cells also showed an in-
crease in internalized CTLA-4. The amount of internal-
ized CTLA-4 increased with TRIM expression
(Figure 3A). However, the net effect was a higher
sCTLA-4 expression over the time course (Figure 3B).
This contrasted with TCR-CD3 expression, previouslyreported to bind to TRIM, that was not affected by in-
creased TRIM expression and ionomycin treatment
(Figure 3C; Bruyns et al., 1998; Kirchgessner et al.,
2001). Taken together, our findings indicate that TRIM
increased CTLA-4 surface expression, leading to in-
creased internalization. However, internalization failed
to fully remove the newly expressed sCTLA-4, allowing
for the retention of increased CTLA-4 on the cell surface.
Upregulation of CTLA-4 by TRIM suggested that TRIM
might indirectly alter T cell function. To test this,
DC27.10-CTLA-4 cells were transfected with HA-TRIM
and either left unstimulated or activated with anti-CD3,
anti-CTLA-4, or anti-CD3 and anti-CTLA-4. After 24 hr,
supernatants were taken and assessed for IL-2
TRIM Modulation of CTLA-4 Expression and Function
813Figure 5. TRIM and CTLA-4 Colocalization and Binding Occurs Mainly Intracellular
(A) Surface CD3 and CTLA-4 from mock (lanes 1, 5) or HA-TRIM (lanes 3, 7)-transfected DC27.10-CTLA-4 cells were precipitated by preincubat-
ing intact cells with anti-CD3 (lanes 1–4) or anti-CTLA-4 (lanes 5–8) at 4C, followed by washing and immunoprecipitation. Lysates were
precleared with Protein A-Sepharose, followed by a second precipitation to purify intracellular CD3 (lanes 2, 4) or CTLA-4 (lanes 6, 8). Precipitates
(lanes 1–8) and anti-CTLA-4 only (lane 9) were blotted with anti-HA. Expression of HA-TRIM and loading controls are shown in cell lysates
immunoblotted with anti-HA and anti-actin, respectively.
(B and C) DC27.10-CTLA-4 cells were transfected with HA-TRIM, fixed in 4% PFA, and permeabilized with saponin. Cells were stained with anti-
CTLA-4 and anti-mouse-Texas red (B) or anti-CD3 and anti-hamster-Texas red (C) either before fixation (surface) or after permeabilization
(intracellular) and anti-HA-FITC to detect HA-tagged TRIM.
(D) Activated human PBLs were fixed, permeabilized, and stained for endogenous TRIM with anti-TRIM and anti-mouse Texas red and CTLA-4
with biotinylated anti-CTLA-4 and Streptavidin-FITC and analyzed by confocal microscopy. The results are representative of at least three
experiments.production (Figure 3D). Anti-CD3 and CTLA-4-mediated
IL-2 production was markedly reduced in TRIM-trans-
fected cells when compared to mock transfectants
(65% versus 35%). Anti-CTLA-4 titration experiments
revealed that the difference between TRIM- and mock
transfected cells was most substantial with suboptimal
concentration of anti-CTLA-4 (i.e., 7% inhibition in
mock transfected cells compared to 56% inhibition in
TRIM transfectants). Similarly, PBLs transiently trans-
fected with HA-TRIM or mock were stimulated with
anti-CD3, anti-CTLA-4, or anti-CD3 and CTLA-4. Prolif-
eration of cells was then assessed after 36 hr. A subse-
quent increase in the inhibitory effect of CTLA-4 was
observed on proliferation in TRIM-transfected primary
T cells (Figure 3D). Compared to mock transfected cells,
increased TRIM expression enhanced CTLA-4-medi-
ated inhibition of proliferation by an additional 34%
(13% versus 47%). In summary, these data demonstrate
that TRIM enhancement of CTLA-4 surface expression
resulted in a marked increase in CTLA-4-mediated
inhibition of T cell function.Downregulation of TRIM by shRNA Reduces CTLA-4
Surface Expression and Inhibition of IL-2 Production
Having demonstrated that TRIM overexpression leads to
an upregulation of CTLA-4 surface expression, we used
a complementary approach with shRNA to downregulate
TRIM expression (Figure 4). Different DC27.10-CTLA-4
TRIM knockdown (KD) clones were identified with greatly
reduced TRIM expression as shown by immunoblotting
(Figure 4A). At the same time, the expression of other
proteins such as VAV-1, SLP-76, MAPK, and actin was
unaffected. Thus, shRNA TRIM resulted in the specific
reduction of TRIM expression.
The reduction of TRIM expression led to reduced ex-
pression of sCTLA-4 when compared to DC27.10-CTLA-
4 WT cells (Figure 4B). TRIM KD cells showed 60% less
sCTLA-4 than WT cells. The total CTLA-4 as detected
by staining of permeabilized cells was unaffected (data
not shown). Further, the expression of surface CD3
(sCD3) was not altered by TRIM (Figure 4B).
Inhibition of anti-CD3-induced IL-2 production by
CTLA-4 was analyzed in DC27.10-CTLA-4 WT and
Immunity
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(A) DC27.10-CTLA-4 cells were transfected with HA-TRIM, fixed in 4% PFA, and permeabilized with saponin. Cells were stained for HA-TRIM with
anti-HA-FITC and Syntaxin 6 with anti-Syntaxin and anti-mouse Texas red or CTLA-4 with biotinylated anti-CTLA-4 and Streptavidin-FITC and
Syntaxin 6 as indicated.
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815TRIM KD cells. WT and TRIM KD cells produced compa-
rable amounts of IL-2 when stimulated with anti-CD3
(data not shown), whereas TRIM KD cells (D2, D11,
D20) stimulated with anti-CD3 and anti-CTLA-4 showed
impaired inhibition of IL-2 production when compared to
WT cells (Figure 4C). Inhibition of IL-2 production in
TRIM KD cells was 50%–60% less than that seen with
WT cells. Overall, these findings confirmed a role for
TRIM in upregulating CTLA-4 expression leading to an
effect on CTLA-4 modulation of T cell function.
TRIM Colocalizes with CTLA-4 in Regions Distinct
from the TCR-CD3 Complex
Because CTLA-4 is found mainly in intracellular com-
partments (Leung et al., 1995; Schneider et al., 1999),
we next assessed the subcellular distribution of CTLA-4
and TRIM (Figure 5). Surface antigen was detected bio-
chemically by preincubating cells with CTLA-4 mAb
prior to washing, detergent solubilization, and immuno-
blotting as previously described (Schneider et al., 1999).
Intracellular antigen was detected by depleting surface
antigens followed by precipitation of the remaining intra-
cellular material. sCD3 and sCTLA-4 as well as intracel-
lular CD3 (iCD3) and iCTLA-4 were immunoprecipitated
and blotted for HA-TRIM (Figure 5A). The majority of
CTLA-4-associated TRIM was found intracellularly. Lit-
tle if any material was detected on the cell surface. In
contrast, anti-CD3 coprecipitated TRIM mainly from
the cell surface with a small amount precipitated in intra-
cellular compartments.
These biochemical results were confirmed by immu-
nofluorescence staining. DC27.10-CTLA-4 cells were
stained with FITC-conjugated anti-HA for detection of
transfected HA-TRIM, whereas CTLA-4 was visualized
with anti-CTLA-4 and Texas red-labeled secondary Ab.
To distinguish between the surface and intracellular lo-
calization of CTLA-4, cells were stained either before or
after fixation and permeabilization. As seen in Figure 5B,
CTLA-4 and TRIM showed similar subcellular distribu-
tion patterns with extensive overlap (white arrow). Both
were detected primarily intracellular with comparatively
low expression at the plasma membrane. A small
amount of CTLA-4 and TRIM colocalization occurred at
the cell surface (top), whereas the majority of those com-
plexes was found in intracellular compartments (bot-
tom). This was in striking contrast with TRIM and the
TCRz-CD3 complex (Figure 5C; Bruyns et al., 1998;
Kirchgessner et al., 2001). In this case, TRIM (FITC-la-
beled) and CD3 colocalization (Texas red) was detected
almost exclusively at the cell surface (Figure 5C, top).
These results confirmed the observation that CTLA-4
and TRIM initially bound in intracellular compartments.
Further, it suggested that once transported to the sur-
face, CTLA-4 and TRIM no longer exist as a complex.
The colocalization of CTLA-4 with endogenous TRIM
was also confirmed in primary T cells (Figure 5D).PBLs were preactivated to induce CTLA-4 expression
and subsequently stained for CTLA-4 and endogenous
TRIM. As in the case of transfected HA-TRIM, colocali-
zation with CTLA-4 occurred mainly in intracellular
vesicles. Therefore, although TRIM associates with
both TCR-CD3 and CTLA-4, there is a marked difference
regarding the site of colocalization. CTLA-4 and TRIM
complexes were detected mainly in intracellular com-
partments, whereas CD3 and TRIM associate at the
plasma membrane.
TRIM and CTLA-4 Colocalize in the trans Golgi
Network
Previous studies have reported the localization of
CTLA-4 in several intracellular compartments including
the trans Golgi network (TGN), lysosomes, and endo-
somes (Iida et al., 2000; Leung et al., 1995; Schneider
et al., 1999). To assess in more detail where CTLA-4
and TRIM colocalize, cells were stained with anti-Syn-
taxin 6, a marker for the Golgi apparatus (Figures 6A
and 6B; Shewan et al., 2003).
As shown in Figure 5B, CTLA-4 was found in a charac-
teristic pattern of clusters of intracellular vesicles. Anti-
TRIM staining overlapped with one set of these CTLA-
4-stained vesicles. A similar pattern was observed for
CTLA-4 and Syntaxin 6 costaining (see arrows Figure 6A,
bottom). Because TRIM staining closely matched anti-
Syntaxin 6 staining (Figure 6A, top), we concluded that
intracellular TRIM and CTLA-4 association mainly oc-
curred in the TGN. This could also be demonstrated in
human PBLs (Figure 6B). Some CTLA-4-containing
vesicles (see blue arrow) colocalized partially with early
lysosomes as defined by anti-Lamp-2 staining (Fig-
ure 6C; Reuter et al., 2004). Only marginal overlap of
CTLA-4 with early endosomal vesicles was observed
as shown by anti-EEA1 (early endosome antigen 1) stain-
ing (Figure 6D; Christoforidis et al., 1999). Thus, the
majority of TRIM and CTLA-4 colocalize in the TGN, the
site from which newly synthesized CTLA-4 is released
to the cell surface.
Modulation of the Localization Pattern
of CTLA-4 by TRIM
To assess whether the localization of CTLA-4 was mod-
ulated by TRIM, DC27-10-CTLA-4–TRIM KD cells were
stained for CTLA-4 and analyzed by confocal micros-
copy. As shown in Figures 6A–6D, the majority of
CTLA-4 in wild-type cells was localized in the Golgi
compartment and several clusters of vesicles, which
partly costained with lyso- and endosomes. This locali-
zation pattern was altered in cells where TRIM expres-
sion was markedly reduced. Most of CTLA-4 in TRIM
KD cells appeared to be centralized (Figure 7A, left)
with fewer surrounding vesicles when compared to
wild-type cells. Costaining for the Golgi marker Syntaxin(B) PBLs were activated with PHA (2.5 mg/ml) for 4 days to induce CTLA-4 expression, fixed in 4% PFA, and permeabilized with saponin. Cells
were stained for endogenous TRIM with goat anti-TRIM and anti-goat Texas red F(ab)2 and Syntaxin 6 with anti-Syntaxin and anti-mouse FITC or
CTLA-4 with biotinylated anti-CTLA-4 and Streptavidin-FITC and Syntaxin 6 with anti-Syntaxin and anti-mouse Texas red as indicated.
(C and D) DC27.10-CTLA-4 cells were transfected with HA-TRIM, fixed in 4% PFA, and permeabilized with saponin. Cells were stained for (C)
CTLA-4 and Lamp-2 with anti-Lamp-2 and anti rat-Texas red; (D) CTLA-4 and EEA1 with anti-EEA1 and anti rabbit-Alexa Fluor 594 and analyzed
by fluorescence microscopy (A, B, C) or confocal microscopy (D). Arrows indicate different sets of CTLA-4-stained vesicles (A, C). Results shown
are representative of at least three experiments.
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816Figure 7. Subcellular Distribution of CTLA-4 Is Altered by TRIM shRNA Knockdown
(A) DC27.10-CTLA-4 TRIM KD and WT cells were fixed in 4% PFA and permeabilized with saponin. Cells were stained with anti-CTLA-4 and anti-
mouse AlexaFluor 647 and analyzed by confocal microscopy (left). Double staining for CTLA-4 and Syntaxin 6 was performed with biotinylated
anti-CTLA-4 and Streptavidin-Alexa Fluor 568 and anti-Syntaxin and anti-mouse Alexa Fluor 647 (right).
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in the Golgi area in TRIM KD cells (Figure 7A, right).
The same change in the pattern of subcellular CTLA-4
localization could be observed in PBLs transiently
transfected with TRIM shRNA when compared to
PBLs transfected with control shRNA (Figure 7B, left).
Although control cells showed CTLA-4 staining in dis-
tinct vesicles throughout the cell, detection of CTLA-4
was restricted to a centralized area in PBLs transfected
with TRIM shRNA. TRIM expression in these cells was
reduced by 80%–85% (Figure 7B, right). Overall, in
TRIM KD cells as well as in primary cells transiently
transfected with TRIM shRNA, there was a marked re-
duction of vesicles between the Golgi area and the
plasma membrane, a result consistent with an impair-
ment of transport from the TGN.
Discussion
Despite its potent effects on T cell function, CTLA-4 is
primarily an intracellular antigen whose surface expres-
sion is tightly regulated (Alegre et al., 1996; Lindsten
et al., 1993; Linsley et al., 1996). This regulation is
achieved by restricted trafficking to the cell surface
and rapid internalization. Even at its highest amounts,
surface CTLA-4 is expressed at about 3% relative to
CD28 (Lindsten et al., 1993). This tight regulation is pre-
sumably due to the need to control surface expression
of this potent coreceptor because minor changes in
surface expression could have major effects on the out-
come of T cell activation. Intracellular CTLA-4 has been
reported to be located in various compartments includ-
ing the TGN, lysosomes, and endosomes (Alegre et al.,
1996; Iida et al., 2000; Leung et al., 1995; Linsley et al.,
1996). However, little is known regarding the regulation
of intracellular trafficking pathways used by CTLA-4 to
reach the plasma membrane. In this study, we demon-
strate that TRIM facilitates the movement of CTLA-4
from the TGN to the surface of T cells. The adaptor
was found to bind to CTLA-4 in intracellular compart-
ments and to colocalize with CTLA-4 in the TGN. The
amounts of CTLA-4–TRIM binding greatly exceeded
that observed for TCR-CD3–TRIM. The interaction was
specific in that it was not observed with CD28. Further,
TRIM overexpression increased sCTLA-4 expression,
whereas the reduction of TRIM expression by shRNA re-
duced sCTLA-4 expression and its ability to inhibit cyto-
kine production. Furthermore, the reduction of TRIM
changed the intracellular localization pattern of CTLA-
4, with the coreceptor being centralized and restricted
to the Golgi compartment. There was a striking reduc-
tion of vesicles between the Golgi area and the plasma
membrane, which are presumably transport vesicles.
Overall, our findings identified a role for TRIM as a chap-
erone that affects T cell function by modulating CTLA-4
cell-surface expression.
CTLA-4 surface expression is a highly dynamic pro-
cess, being recycled between intracellular stores and
the cell surface. Upon T cell activation, CTLA-4 isreleased toward the immunological synapse, the site of
TcR-CD3–APC engagement (Linsley et al., 1996). Punc-
tual and directed CTLA-4 surface expression is essential
for its function at the immunological synapse and modu-
lation of T cell activation. Previous studies have shown
that CTLA-4 externalization can be augmented by in-
creased intracellular Ca2+ concentrations and by muta-
tion of the YVKM motif (Linsley et al., 1996; Yi et al.,
2004). Mutation of the tyrosine in this motif will enhance
CTLA-4 surface expression (Yi et al., 2004). As in the case
of many receptors, phospholipase D (PLD) and small
ADP ribosylation factor (ARF) are required for transport
of CTLA-4 from the TGN to the cell surface (Mead et al.,
2005). Presumably, other key regulators of trafficking
(i.e., SNAREs) are also needed for CTLA-4 expression.
TRIM differs from these mediators in specifically binding
to CTLA-4. This immune-specific interaction presumably
operates in conjunction with more general constituents
involved in the trafficking process. The manner by which
this complex interacts with generic events remains to be
determined.
The ability of TRIM to increase cell-surface expression
was demonstrated by pulse-chase and FACS analysis.
Pulse-labeled CTLA-4 appeared more quickly and at
higher amounts on the surface of T cells in TRIM-trans-
fected cells, whereas FACS analysis showed TRIM-
mediated increased CTLA-4 surface expression leading
to increased internalization. However, increased inter-
nalization failed to fully remove the newly expressed
sCTLA-4, resulting in retention of increased CTLA-4 on
the cell surface. In this regard, increased internalization
is most likely a reflection of the capacity of the endocytic
process to accommodate newly expressed sCTLA-4. It
is unlikely to reflect an actual increase in the role of inter-
nalization per se. Overall, this finding suggests that not
only does TRIM associate with CTLA-4 and colocalize
in the TGN, but serves as a shuttle protein to facilitate
CTLA-4 surface expression. Independent of TRIM bind-
ing, CTLA-4 is translocated to endo- and lysosomes,
and either degraded or recycled to the cell surface.
Rapid endocytosis of CTLA-4 is facilitated by AP-2
(Bradshaw et al., 1997; Chuang et al., 1997; Shiratori
et al., 1997; Zhang and Allison, 1997), whereas AP-1 reg-
ulates trafficking from the Golgi to lysosomal compart-
ments (Schneider et al., 1999). The binding of TRIM to
CTLA-4 occurs independently of AP-1 and AP-2 binding.
Mutation of the Y201 residue in CTLA-4 cytoplasmic tail
abrogates AP-1–AP-2 binding (Schneider et al., 1999),
whereas binding to TRIM was not influenced.
The properties associated with TRIM and CTLA-4
binding are distinct from those linked to TRIM and
TCR-CD3. Although TRIM–CTLA-4 binding occurs
mainly inside the cells leading to increased surface ex-
pression, the binding of TRIM to TCR-CD3 occurs pri-
marily at the cell surface. Little if any TRIM was found as-
sociated with CTLA-4 on the cell surface. This finding is
in agreement with a model in which TRIM facilitates
CTLA-4 surface expression followed by TRIM dissocia-
tion from CTLA-4 and binding of TRIM to the TCR-CD3(B) PBLs were transfected with TRIM shRNA and stimulated with PHA (2.5 mg/ml) for 3 days. Cells were fixed in 4% PFA, permeabilized with
saponin, and stained for CTLA-4 with biotinylated anti-CTLA-4 and Streptavidin-Alexa Fluor 568. Mock and shRNA-TRIM-transfected cells
were analyzed by confocal microscopy (left). TRIM expression in PBLs and shRNA TRIM-transfected cells was assessed by immunoblotting
(data not shown) and densitometric analysis (right). Results are representative of at least two experiments.
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818complex. TRIM overexpression did not alter the expres-
sion of the TCR-CD3 complex in a hybridoma and pri-
mary T cells. Further, the function of TRIM mediated re-
lease of CTLA-4 to the cell surface is in contrast to the
mechanism described for enhanced TCR-CD3 expres-
sion mediated by the association with TRIM. The interac-
tion of TRIM with TCR-CD3 leads to reduced internaliza-
tion of the TcR-CD3 complex (Kirchgessner et al., 2001),
whereas the interaction of TRIM with CTLA-4 leads to in-
creased externalization of CTLA-4 in DC27.10-CTLA-4
cells as well as in primary T cells. The differences in the
proposed mechanisms of TRIM-mediated enhanced
surface expression of CD3 and CTLA-4, respectively, is
reflected in the main sites of colocalization. While TcR-
CD3–TRIM interaction has been observed mainly at the
cell surface, CTLA-4–TRIM association occurs predom-
inately in the TGN. Increased TcR-CD3 expression medi-
ated by TRIM overexpression is reported for the Jurkat T
cell line (Kirchgessner et al., 2001). It is possible that this
cell line has its own property in terms of reduced internal-
ization of the TCR-CD3 complex after TRIM transfection.
Also, other studies on the Jurkat T cell line found that
there is no requirement for CD28-PI3-kinase binding in
anti-CD3-induced IL-2 production. This contrasts with
results obtained from other cell lines and is likely due
to the loss of the phosphatase and tensin homolog
PTEN in Jurkat cells (Shan et al., 2000). During the prep-
aration of this manuscript, Ko¨lsch et al. reported that in
TRIM-deficient mice there is no alteration in TCR-CD3
expression when compared to wild-type mice (Ko¨lsch
et al., 2006).
TRIM expression was found to potentiate surface ex-
pression of CTLA-4 with the net effect to enhance indi-
rectly the suppression of T cell activation (i.e., IL-2 pro-
duction, proliferation). CTLA-4 is present in enlarged,
abnormal vesicles in Chediak Higashi syndrome (CHS),
and T cells from patients suffering from CHS were shown
to be defective in cycling CTLA-4 to the cell surface after
stimulation. Therefore, defective surface expression of
CTLA-4 by CHS T cells is involved in the generation of
lymphoproliferative disease (Barrat et al., 1999). Our
data show that TRIM modulates T cell responses by af-
fecting CTLA-4 surface expression. Although the effect
of TRIM on CTLA-4 function is due to an increase in
CTLA-4 surface expression, further functions for TRIM
cannot be excluded. TRIM might additionally enhance
CTLA-4 signaling directly as a typical adaptor protein
by recruiting downstream signaling elements (i.e., PI3-
kinase, src-kinases) (Bruyns et al., 1998). It is unlikely
that TRIM itself can operate to facilitate a negative im-
mune response, independently of CTLA-4, given that
the adaptor failed to modulate T cell responses on its
own (Bruyns et al., 1998; Kirchgessner et al., 2001;
Ko¨lsch et al., 2006). The mild phenotype of the TRIM-
deficient mice suggests that other nonraft TRAPs may
compensate for the absence of TRIM (Ko¨lsch et al.,
2006). Other TRAPs may eventually be found to associ-
ate with CTLA-4. For example, LAX-deficient T and B
lymphocytes are hyperresponsive to anti-CD3 and anti-
IgM-mediated stimulation (Zhu et al., 2005), and SIT-de-
ficient mice show an increased susceptibility to develop
experimental autoimmune encephalomyelitis (Simeoni
et al., 2005). It is not surprising that TRIM-deficient
mice failed to show an autoimmune phenotype becausethe knockdown of TRIM in our study did not lead to
a complete loss of surface CTLA-4. This result suggests
that there are other proteins involved in the regulation of
CTLA-4 expression.
Our findings demonstrating that TRIM facilitates
CTLA-4 surface expression followed by TRIM dissocia-
tion and association with the TCR-CD3 complex on
the cell surface suggest that TRIM may promote CD3–
CTLA-4 localization at the immunological synapse,
which has been shown to be a crucial event in CTLA-4-
mediated inhibition of T cell activation (Darlington et al.,
2002; Egen and Allison, 2002). An intriguing aspect of
TRIM is its ability to associate with both of these two cen-
tral receptors in the regulation of T cell activation. The
functional relevance of interconnecting the TCR-CD3
complex and CTLA-4 remains to be elucidated.
Experimental Procedures
Cells and Reagents
DC27.10-CTLA-4 cells were cultured in RPMI media supplemented
with fetal calf serum as described elsewhere (Cai et al., 1995;
Schneider et al., 1999). Human peripheral T cells were isolated
from buffy-coats from healthy individuals (Colingdale and Adden-
brooke’s NHS Blood Donor Service, London and Cambridge, UK)
as described (Schneider et al., 1999). Anti-human CD3 (OKT3) and
anti-SLP-76 were obtained from American Type Culture Collection.
Anti-human CTLA-4 (BNI3) was kindly provided by B. Broeker
(Greifswald, Germany). Anti-mouse CD3 (145-2C11), anti-mouse
CTLA-4 (UC10-4F10-11), and anti-mouse CD28 (37.51) were pur-
chased from BD Pharmingen.
Antibodies and reagents used for immunofluorescence staining
and biochemistry were purchased as follows: anti-TRIM (TRIM-04)
and anti-EEA1 from abcam; anti-human CTLA-4-biotin, anti-hu-
man-CD3-FITC, anti-Syntaxin 6, and Streptavidin-FITC from BD Bio-
sciences; anti-Lamp2 (ABL-93) from Southern Biotech; anti-mouse-
Texas Red and anti-mouse-FITC from Jackson ImmunoResearch;
anti-HA-FITC from Covance; anti-human CTLA-4-PE and mouse
IgG2a-PE from Beckman Coulter; and anti-rabbit-Alexa Fluor 594,
anti-mouse Alexa Fluor 647, and Streptavidin-Alexa Fluor 568 from
Molecular Probes. Anti-VAV and anti-MAPK antibodies were from
New England Biolabs.
Plasmid Construction
Full-length human TRIM cDNA was isolated via RT-PCR. Total RNA
was isolated from anti-CD3-stimulated Jurkat cells with the Trizol
reagent (Invitrogen). PCR primer sequences were sense, 5-ccgaaaa
aaagaagcatgtcagg-3 and antisense, 5-catggtccagctagtttataggttc-3.
The amplified products were ligated into the TA cloning vector (Invi-
trogen) and confirmed by DNA sequencing. An expression vector
encoding the influenza virus hemagglutinin (HA)-tagged TRIM was
constructed by cloning the 560 bp SacI-KpnI fragment of TRIM into
the SacI-KpnI site of the expression vector pSRa in-frame with the
HA-tag at the C terminus.
The template for mouse TRIM shRNA were generated by ligating
the annealed primers 50-acctcggatgagaactgctatgaacatcaagagtgttc
atagcagttctcatcctt-30 and 50-caaaaaggatgagaactgctatgaacactcttga
tgttcatagcagttctcatccg-30 and 50-acctcgctatgcctcactggatcacatcaa
gagtgtgatccagtgaggcatagctt-30 and 50-caaaaagctatgcctcactggatca
cactcttgatgtgatccagtgaggcatagcg-30 into the BbsI sites of psiRNA-
hH1GFPzeo G2 vector (InvivoGen). As a control, the primers 50-ac
ctcgcgttaattagactgaggagttcaagagactcctcagtctaattaacgctt-30 and
50-caaaaagcgttaattagactgaggagtctcttgaactcctcagtctaattaacggg-30
were used. Designed RNA oligonucleotides were blasted against
the GenBank/EMBL/DDBJ database to ensure gene specificity.
The construction of the CTLA-4 plasmids (wild-type and mutants)
is described (Schneider et al., 1999).
Transfections
DC27.10-CTLA-4 cells or PBLs were transiently transfected by
a standard electroporation protocol (Schneider et al., 1999) or by
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819the Amaxa Nucleofector Kit, respectively. 18 hr (for PBLs) and 24 hr
(for DC27.10-CTLA-4 cells) after transfection, cells were stimulated
as described below.
Interleukin-2 Assay
DC27.10-CTLA-4 and DC27.10-CTLA-4 TRIM KD cells (1 3 105/200
ml) were stimulated with plate-bound anti-CD3 (1 mg/ml) and anti-
CTLA-4 (10 mg/ml, 20 mg/ml). After 24 hr, supernatants were taken
and IL-2 concentration determined by ELISA (BD Biosciences)
according to manufacturer’s protocol.
Proliferation Assay
Purified naive T cells were cultured at a density of 23 105/200 ml cells
in the presence of mitomycin C-treated autologous APCs (ratio 5:1)
in anti-CD3 (2 mg/ml) and anti-CTLA-4 (10 mg/ml)-coated 96-well
plates for 36 hr. To assess proliferation, cells were pulsed with
1 mCi of [3H]thymidine for the last 12 hr of the indicated period of
time.
Flow Cytometry and Immunofluorescence
To analyze CTLA-4 expression, cells were stained for surface CTLA-4
with CTLA-4-PE mAb or PE-labeled isotype control antibody. Alter-
natively, CTLA-4 was labeled with anti-CTLA-4 and anti-mouse-
APC secondary antibody and only secondary antibody as control.
For intracellular HA-TRIM staining, cells were fixed in 4% paraformal-
dehyde (PFA) (Sigma), permeabilized with 0.3% saponin (Sigma),
and stained with anti-HA-FITC in saponin containing PBS/BSA. Cells
were fixed and analyzed with a FACSCalibur flow cytometer.
For immunofluorescence staining, cells were fixed in 4% PFA,
permeabilized with 0.3% saponin, and stained with anti-CD3,
anti-CTLA-4, anti-Syntaxin, anti-TRIM, and appropriate fluoro-
chrome-labeled secondary antibody or anti-HA-FITC, respectively.
Additionally, biotinylated anti-CTLA-4 and fluorochrome-labeled
Streptavidin were used. Negative controls were run with unstained,
single-stained samples, or omitting primary antibody. Stained cells
were mounted on slides and analyzed by fluorescence microscopy.
Ionomycin-Induced CTLA-4 Surface Expression
Isolated human PBLs were stimulated with 1 mM ionomycin (Sigma)
for up to 3 hr at 37C. Samples were stored on ice and subse-
quently stained for CTLA-4 and HA-TRIM expression as indicated.
To determine exocytosis of CTLA-4 over time, PBLs were labeled
with anti-CTLA-4-PE in AIMV medium plus 2% FCS for 30 min on
ice and subsequently activated with ionomycin at 37C in the pres-
ence of anti-CTLA-4-PE (1 mg/ml) for up to 3 hr. At the indicated
times, cells were washed once with PBS and fixed in 2% PFA,
and total cell-associated fluorescence was analyzed by flow
cytometry.
For comparison of total cell-associated fluorescence (surface and
internalized CTLA-4) and intracellular PE fluorescence (internalized
CTLA-4), samples were divided in two parts. One part was left un-
treated, while the other was incubated on ice for 45 s in PBS acidified
to pH 2.0 and supplemented with 0.03 M sucrose and 10% FCS
(Cefai et al., 1998) to remove surface-bound antibody. Cells were
washed and analyzed by FACS. Untreated samples account for total
cell-associated fluorescence, while acid-stripped aliquots account
for PE fluorescence in acid-resistant (internal) compartments.
Immunoprecipitation and Immunoblotting
For immunoprecipitation, cells were lysed in ice-cold lysis buffer
containing 1% TritonX-100 in 20 mM Tris-HCl (pH 8.3), 150 mM
NaCl. The lysis buffer contained protease and phosphatase inhibi-
tors. Postnuclear lysates were incubated for 1 hr with the indicated
antibody. Protein A-Sepharose beads (30 ml, Amersham Pharmacia)
were added and incubated for 1 hr at 4C. The eluted proteins (non-
reducing conditions for CD28 and detection of endogenous TRIM)
were separated by SDS-PAGE and transferred to nitrocellulose for
immunoblotting. The membranes were blocked with 5% milk in
TBS (10 mM Tris-HCl [pH 7.6], 150 mM NaCl) and incubated with
the indicated antibody. Bound antibody was revealed with the
appropriate secondary antibody, and protein was visualized by
enhanced chemiluminescence (ECL, Amersham).Metabolic Labeling
To monitor CTLA-4 surface expression of newly synthesized CTLA-4
in mock or TRIM-transfected DC27.10-CTLA-4 cells, cells were
pulsed with [35S]methionine for 20 min and chased with nonradioac-
tive methionine for the indicated periods of time in the presence of
ionomycin (1 mM). Surface CTLA-4 from both transfectants was
precipitated by preincubating labeled cells with anti-CTLA-4 at
4C, followed by washing and immunoprecipitation. Lysates were
subjected to preclearing with Protein A-Sepharose, followed by
a second precipitation to purify intracellular CTLA-4. The immuno-
precipitates were analyzed by 10% SDS-PAGE.
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